Back to all papers

An integrated radiomics-pathomics approach for predicting efficacy and prognosis of immunotherapy in advanced non-small cell lung cancer.

August 26, 2026pubmed logopapers

Authors

Liang Z,Zeng N,Pei M,Li C,Zhu J,Wen Z

Affiliations (5)

  • Department of Radiology, Zhujiang Hospital, Southern Medical University, 253 Gongye Middle Avenue, Haizhu District, Guangzhou, Guangdong, China.
  • Department of Radiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510120, China.
  • Department of Pathology, Zhujiang Hospital, Southern Medical University, 253 Gongye Middle Avenue, Haizhu District, Guangzhou, Guangdong, China.
  • Department of Radiology, Zhujiang Hospital, Southern Medical University, 253 Gongye Middle Avenue, Haizhu District, Guangzhou, Guangdong, China. [email protected].
  • Department of Radiology, Zhujiang Hospital, Southern Medical University, 253 Gongye Middle Avenue, Haizhu District, Guangzhou, Guangdong, China. [email protected].

Abstract

To develop a multimodal model for predicting progression-free survival (PFS) and survival probability of immunotherapy in patients with advanced non-small-cell lung cancer (NSCLC). This retrospective study included 182 inoperable NSCLC patients treated with immune checkpoint inhibitors. The primary endpoint was defined as durable clinical benefit (DCB, PFS ≥ 6 months) and non-durable clinical benefit (NDB, PFS < 6 months). Overall survival (OS) was the secondary endpoint for long-term efficacy. Clinical characteristics were selected using univariate and multivariate regression analyses. Radiomics features were extracted from pre-treatment computed tomography (CT) images, and pathomics features were extracted from whole slide images. A multimodal integrated model was constructed by combining clinical characteristics, radiomics-pathomics features, and utilizing multiple machine learning classifiers. The performance of the model was evaluated by plotting the receiver operating characteristic (ROC) curves and calculating the area under the curves (AUC). Kaplan-Meier survival analysis and Cox regression analysis were applied to analyze OS. The multimodal model using Logistic regression classifier demonstrated better predictive performance in distinguishing DCB from NDB than any unimodal models (including the clinical, radiomics and pathomics model), with AUC of 0.90 (95%CI: 0.82-0.98) in the test cohort. Kaplan-Meier analysis and Cox regression analysis revealed significant survival differences between DCB and NDB groups stratified by the multimodal model. Two nomograms were developed to predict DCB and survival probabilities, respectively. The combination of radiomics and pathomics features showed complementary value in predicting the efficacy and prognosis of immunotherapy, potentially improving individualized treatment in NSCLC.

Topics

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyImmune Checkpoint InhibitorsJournal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.